Table 2 Median duration of multimodality cancer treatments in weeks
n (%) | Diagnosis to first treatment (IQR) | Chemotherapy (IQR) | Radiation (IQR) | Time between treatments (1) (IQR)b | Time between treatments (2) (IQR)b | Overall cancer treatment (IQR) | |
|---|---|---|---|---|---|---|---|
BREAST, n = 12,415 | |||||||
Surgery Only | 4463 (35.9) | 5.7 (3.9–8.1) | |||||
Surgery + Radiotherapy | |||||||
Neoadjuvant XRT | 26 (0.2) | 29.1 (25.9–32.5) | 5.4 (4.5–5.7) | 6.9 (5.1–9.0) | 11.9 (10.4–14.3) | ||
Adjuvant XRT | 2436 (19.6) | 5.0 (3.7–7.1) | 3.6 (3.1–4.3) | 12.1 (9.6–18.1) | 16.0 (13.3–22.4) | ||
Surgery + Chemotherapy | |||||||
Neoadjuvant Chemo | 495 (4.0) | 5.0 (3.9–7.9) | 15.0 (12.1–20.9) | 6.1 (4.4–12.9) | 23.9 (19.4–28.0) | ||
Adjuvant Chemo | 2714 (21.9) | 5. 0 (3.6–6.6) | 14.3 (9.0–20.6) | 8.0 (6.3–10.3) | 22.4 (18.1–28.1) | ||
Surgery + Chemotherapy + Radiotherapy | |||||||
Surgery > > Adj Chemo > > Adj XRT | 1895 (15.3) | 4.9 (3.4–6.3) | 14.0 (9.0–16.1) | 4.0 (3.1–5.4) | 8.3 (6.6–10.9) | 5.0 (4.0–8.3) | 33.9 (29.3–38.6) |
Chemo > > Surgery > > Adj XRT | 310 (2.5) | 5.0 (3.4–8.0) | 14.5 (9.0–19.8) | 5.3 (3.4–5.7) | 6.1 (4.4–10.3) | 7.8 (6.1–10.2) | 35.7 (31.7–40.9) |
Chemo > > XRT > > Surgery | 76 (0.6) | 5.6 (3.6–13.8) | 15.0 (9.0–21.7) | 5.4 (4.0–5.9) | 4.6 (3.6–7.7) | 6.9 (5.3–9.0) | 35.3 (27.9–40.0) |
Total Treatment Timea | 7952 (64.1) | 24.6 (17.0–32.3) | |||||
COLORECTAL, n = 4988 | |||||||
Surgery Only | 2895 (58.0) | 3.0 (0.0–6.3) | |||||
Surgery + Radiotherapy | |||||||
Neoadjuvant XRT | 116 (2.3) | 7.9 (6.0–9.9) | 0.6 (0.6–0.9) | 1.2 (0.9–2.0) | 2.0 (1.4–2.6) | ||
Adjuvant XRT | 23 (0.5) | 3.9 (0.0–7.4) | 5.0 (3.9–5.4) | 9.0 (6.9–11.7) | 14.4 (10.9–17.1) | ||
Surgery + Chemotherapy | |||||||
Neoadjuvant Chemo | 68 (1.4) | 6.1 (4.3–8.0) | 5.1 (4.0–5.9) | 8.9 (7.3–10.7) | 13.9 (12.3–15.1) | ||
Adjuvant Chemo | 1501 (30.1) | 4.0 (0.4–8.1) | 20.9 (9.1–22.6) | 8.3 (6.7–11.4) | 28.7 (22.1–32.1) | ||
Surgery + Chemotherapy + Radiotherapy | |||||||
Surgery > > ChemoXRT | 84 (1.7) | 3.5 (0.1–7.3) | 14.0 (5.9–18.5) | 8.9 (6.9–13.4) | 29.6 (14.9–34.3) | ||
ChemoXRT > > Surgery | 170 (3.4) | 7.5 (6.1–9.5) | 6.0 (5.0–14.0) | 7.4 (6.1–8.7) | 14.0 (12.0–15.9) | ||
XRT > > Surgery > > Adj Chemo | 67 (1.3) | 8.00 (6.3–10.0) | 21.0 (5.4–23.0) | 0.9 (0.6–0.9) | 1.1 (0.7–1.7) | 9.7 (7.1–11.9) | 31.0 (24.3–35.3) |
ChemoXRT > > Surgery > > Chemo | 64 (1.3) | 7.3 (5.9–9.9) | 34.6 (29.9–37.4) | 34.6 (29.9–37.4) | |||
Total Treatment Timea | 2093 (42.0) | 26.7 (14.3–31.4) | |||||
LUNG, n = 2044 | |||||||
Surgery Only | 1067 (52.2) | 0.0 (0.0–6.7) | |||||
Radiotherapy Only | 190 (9.3) | 11.1 (6.8–17.4) | 3.2 (1.4–5.9) | 3.2 (1.4–5.9) | |||
Sequential Chemo > > Radiotherapy | 92 (4.5) | 8.9 (4.5–13.7) | 9.3 (6.3–10.3) | 5.4 (3.0–6.1) | 6.3 (1.0–9.3) | 19.1 (10.9–25.0) | |
Combined Chemoradiotherapy | 421 (20.6) | 6.7 (4.2–9.1) | 6.9 (6.0–10.3) | 6.9 (6.0–10.3) | |||
Surgery + Radiotherapy | |||||||
Neoadjuvant XRT | 4 (0.2) | 7.4 (5.8–11.7) | 6.0 (5.3–7.0) | 10.0 (4.8–21.3) | 16.6 (10.0–27.6) | ||
Adjuvant XRT | 6 (0.3) | 8.1 (0.0–12.8) | 1.9 (1.3–4.0) | 13.3 (11.6–16.4) | 15.8 (12.8–21.3) | ||
Surgery + Chemotherapy | |||||||
Adjuvant Chemo | 214 (10.5) | 5.9 (0.0–9.9) | 10.0 (6.4–11.0) | 8.6 (7.3–10.0) | 18.4 (15.1–20.8) | ||
Surgery + Chemotherapy + Radiotherapy | |||||||
ChemoXRT > > Surgery | 29 (1.4) | 7.6 (5.9–10.1) | 6.1 (5.2–9.3) | 7.4 (5.7–13.7) | 18.0 (11.1–29.3) | ||
Surgery > > ChemoXRT | 21 (1.0) | 4.3 (0.0–8.4) | 9.9 (5.8–11.6) | 8.0 (6.4–11.4) | 26.6 (18.7–35.6) | ||
Total Treatment Timea | 977 (47.8) | 9.1 (6.0–16.3) | |||||
PROSTATE, n = 2828 | |||||||
Surgery Only | 1134 (40.1) | 13.0 (9.4–18.8) | |||||
Definitive Radiotherapy Only | 654 (23.1) | 33.1 (24.0–43.1) | 5.9 (4.9–7.6) | 5.9 (4.9–7.6) | |||
Brachytherapy | 1014 (35.9) | 25.3 (18.9–34.9) | |||||
Surgery + Radiotherapy | |||||||
Adjuvant XRT (within 3 months) | 26 (0.9) | 9.2 (6.5–15.8) | 6.7 (6.5–7.0) | 10.0 (9.3–11.5) | 17.1 (16.1–18.1) | ||
Total Treatment Timea | 680 (24.0) | 6.0 (4.9–7.6) | |||||